Salarius Pharmaceuticals, Inc.
NASDAQ Capital MarketTotal Valuation
Salarius Pharmaceuticals, Inc. carries a market capitalization of 4.92M, placing it among publicly traded companies globally.
| Market Cap | 4.92M |
| Enterprise Value | N/A |
Share Statistics
Salarius Pharmaceuticals, Inc. currently has 78,707.00 shares outstanding.
| Shares Outstanding | 78,707.00 |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 0.00 |
| P/TBV Ratio | 0.02 |
| P/FCF Ratio | -0.02 |
| P/OCF Ratio | -0.02 |
Financial Position
Salarius Pharmaceuticals, Inc. maintains a current ratio of 3.28, meaning it holds 3.3x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 3.28 |
| Quick Ratio | 2.71 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -100.54 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Salarius Pharmaceuticals, Inc.'s stock has declined approximately -97.21393% over the past 52 weeks. The 50-day moving average sits at 1.12, while the 200-day moving average is 6.94.
| Beta (5Y) | N/A |
| 52-Week Price Change | -97.21393% |
| 50-Day Moving Average | 1.12 |
| 200-Day Moving Average | 6.94 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -5.06M, while operating income came in at -5.07M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -5.07M |
| Pretax Income | -5.00M |
| Net Income | -5.00M |
| EBITDA | -5.06M |
| EBIT | -5.07M |
| Earnings Per Share (EPS) | -245.46 |
Balance Sheet
Total book value stands at -85.46M, with working capital of 4.22M providing operational flexibility.
| Cash & Cash Equivalents | 4.81M |
| Total Debt | N/A |
| Net Debt | -4.81M |
| Equity (Book Value) | -85.46M |
| Book Value Per Share | -4,191.55 |
| Working Capital | 4.22M |
Cash Flow
Salarius Pharmaceuticals, Inc. produced -4.43M in operating cash flow over the past twelve months.
| Operating Cash Flow | -4.43M |
| Capital Expenditures | N/A |
| Free Cash Flow | -4.43M |
| FCF Per Share | -217.42 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -8,230.47 |
| FCF Yield | -5,924.38 |
Stock Splits
Salarius Pharmaceuticals, Inc.'s most recent stock split took place on August 18, 2025 with a 15:1 split ratio.
| Last Split Date | 8/18/2025 |
| Split Ratio | 15:1 |
Scores
Salarius Pharmaceuticals, Inc. posts an Altman Z-Score of -21.51, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -21.51 |